IL141403A0 - Deleted adenoviruses and methods of making and administering the same - Google Patents
Deleted adenoviruses and methods of making and administering the sameInfo
- Publication number
- IL141403A0 IL141403A0 IL14140399A IL14140399A IL141403A0 IL 141403 A0 IL141403 A0 IL 141403A0 IL 14140399 A IL14140399 A IL 14140399A IL 14140399 A IL14140399 A IL 14140399A IL 141403 A0 IL141403 A0 IL 141403A0
- Authority
- IL
- Israel
- Prior art keywords
- administering
- making
- methods
- same
- deleted adenoviruses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14574298P | 1998-08-28 | 1998-08-28 | |
PCT/US1999/019540 WO2000012740A2 (en) | 1998-08-28 | 1999-08-27 | ADENOVIRUSES DELETED IN THE IVa2, 100K AND/OR PRETERMINAL PROTEIN SEQUENCES |
Publications (1)
Publication Number | Publication Date |
---|---|
IL141403A0 true IL141403A0 (en) | 2002-03-10 |
Family
ID=22514327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14140399A IL141403A0 (en) | 1998-08-28 | 1999-08-27 | Deleted adenoviruses and methods of making and administering the same |
Country Status (8)
Country | Link |
---|---|
US (3) | US6328958B1 (ja) |
EP (1) | EP1108049A2 (ja) |
JP (1) | JP2002528056A (ja) |
CN (1) | CN1342206A (ja) |
AU (2) | AU764686B2 (ja) |
CA (1) | CA2340276A1 (ja) |
IL (1) | IL141403A0 (ja) |
WO (1) | WO2000012740A2 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1108049A2 (en) * | 1998-08-28 | 2001-06-20 | Duke University | Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences |
IT1302403B1 (it) | 1998-11-06 | 2000-09-05 | Angeletti P Ist Richerche Bio | Cellule per la produzione di vettori adenovirali difettivi, metodoper la loro preparazione e loro uso. |
US6764674B1 (en) * | 1999-01-28 | 2004-07-20 | Onyx Pharmaceuticals Inc. | Adenovirus E1B shuttle vectors |
AU1775901A (en) * | 1999-11-17 | 2001-05-30 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
US6867022B1 (en) * | 2000-01-21 | 2005-03-15 | Regents Of The University Of Michigan | Replication deficient adenovirus vectors and methods of making and using them |
WO2001070763A1 (en) * | 2000-03-22 | 2001-09-27 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
AU5882801A (en) | 2000-05-26 | 2001-12-03 | Sumitomo Pharmaceuticals Company, Limited | Novel recombinant adenovirus vector with relieved side effects |
WO2002081648A2 (en) * | 2001-04-09 | 2002-10-17 | The United States of America, represented by The Secretary, Department of Health & Human Services | Synthesis and secretion of recombinant lysosomal enzymes by liver |
US6946126B2 (en) * | 2001-06-04 | 2005-09-20 | Duke University | Replicating adenovirus vectors |
CA2457694A1 (en) * | 2001-08-09 | 2003-02-20 | Cornell Research Foundation, Inc. | Platelet-derived growth factor protection of cardiac myocardium |
AU2003224880A1 (en) | 2002-04-05 | 2003-10-27 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy |
US7090836B2 (en) * | 2002-06-21 | 2006-08-15 | Institut Pasteur | Vector for expressing α-L-iduronidase and method of treating MPS I by stereotactic injection into the brain of a mammal |
US7803365B2 (en) * | 2002-12-02 | 2010-09-28 | Biovec, Llc | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
US9388427B2 (en) | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
WO2004064750A2 (en) | 2003-01-22 | 2004-08-05 | Duke University | Improved constructs for expressing lysosomal polypeptides |
WO2004073624A2 (en) | 2003-02-14 | 2004-09-02 | The Curators Of The University Of Missouri | Contraceptive methods and compositions related to proteasomal interference |
CA2515916A1 (en) * | 2003-02-25 | 2004-09-10 | Biovec B.V. | Therapeutic applications of thrombomodulin gene via viral and non-viral vectors |
US7129049B2 (en) * | 2003-12-22 | 2006-10-31 | Regents Of The University Of Minnesota | Method of detecting equine glycogen storage disease IV |
US20080044393A1 (en) * | 2004-07-16 | 2008-02-21 | White Robert L | Retinal dystrophin transgene and methods of use thereof |
JP5098014B2 (ja) * | 2004-11-18 | 2012-12-12 | 国立大学法人広島大学 | 遺伝子増幅により形成された反復配列から、発現抑制されているタンパク質を発現させる方法、キット、および形質転換体 |
GB0606190D0 (en) | 2006-03-28 | 2006-05-10 | Isis Innovation | Construct |
WO2009149252A1 (en) * | 2008-06-04 | 2009-12-10 | Cornell University | Vaccines for prevention and treatment of addiction |
US8679478B2 (en) | 2010-10-04 | 2014-03-25 | Duke University | Methods of lysosomal storage disease therapy |
EP2638152B1 (en) * | 2010-11-08 | 2016-08-31 | Amicus Therapeutics, Inc. | Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity |
US20140155469A1 (en) | 2011-04-19 | 2014-06-05 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors and viruses |
TWI698240B (zh) | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
CN105189542A (zh) | 2013-02-20 | 2015-12-23 | 瓦莱里昂治疗有限责任公司 | 用于治疗庞贝氏症的方法和组合物 |
WO2015142941A1 (en) | 2014-03-17 | 2015-09-24 | Avalanche Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
US11021519B2 (en) | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
WO2016172155A1 (en) | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation of aav vector transgene expression |
US10967073B2 (en) | 2015-05-07 | 2021-04-06 | The Mclean Hospital Corporation | Glucocerebrosidase gene therapy for Parkinson's disease |
US10940125B2 (en) | 2015-09-18 | 2021-03-09 | Duke University | Methods and compositions for the treatment of steatosis-associated disorders |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
WO2019073059A1 (en) * | 2017-10-12 | 2019-04-18 | Freeline Therapeutics Limited | ADENOVIRAL AUXILIARY VIRUSES WITH DEFECTIVE CYCLE LIFE, PRODUCTION AND USE FOR THE PRODUCTION OF RAAV |
CN108203706B (zh) * | 2017-11-30 | 2021-03-26 | 陕西师范大学 | 一种用于提高高容量腺病毒包装效率的辅助腺病毒 |
CN110724710A (zh) * | 2019-10-28 | 2020-01-24 | 扬州大学 | 一种控制猪pfkm表达的载体及其应用 |
RU2731356C9 (ru) * | 2020-08-22 | 2021-10-05 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты) |
RU2731342C9 (ru) * | 2020-08-22 | 2021-10-05 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты) |
BR112022003581A2 (pt) * | 2020-08-22 | 2022-08-16 | Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte | Vetor de expressão contra o vírus da síndrome respiratória aguda grave sars-cov-2 |
EA037297B9 (ru) * | 2020-08-22 | 2021-11-24 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома sars-cov-2 (варианты) |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674722A (en) | 1987-12-11 | 1997-10-07 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
ES2093642T3 (es) | 1988-12-23 | 1997-01-01 | Genzyme Corp | Celulas cho que producen gluco-cerebrosidasa re-combinante enzimaticamente activa. |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
NL9101680A (nl) * | 1991-10-04 | 1993-05-03 | Tno | Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren. |
US5518913A (en) | 1991-10-10 | 1996-05-21 | National Research Council Of Canada | High level recombinant protein production using conditional helper-free adenovirus vector |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
ATE399873T1 (de) | 1993-07-13 | 2008-07-15 | Centelion | Defekte adenovirus-vektoren und deren verwendung in der gentherapie |
US5928944A (en) | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
CA2117668C (en) | 1994-03-09 | 2005-08-09 | Izumu Saito | Recombinant adenovirus and process for producing the same |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
CA2192442C (en) | 1994-06-10 | 2007-09-25 | Imre Kovesdi | Complementary adenoviral vector systems and cell lines |
FR2724945B1 (fr) * | 1994-09-27 | 1996-12-27 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en therapie genique |
AU704391B2 (en) * | 1994-10-28 | 1999-04-22 | Trustees Of The University Of Pennsylvania, The | Improved adenovirus and methods of use thereof |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US5980886A (en) | 1994-12-14 | 1999-11-09 | University Of Washington | Recombinant vectors for reconstitution of liver |
US5880102A (en) | 1995-01-17 | 1999-03-09 | Duke University | Adenoviral vector system |
FR2730504B1 (fr) | 1995-02-13 | 1997-03-28 | Rhone Poulenc Rorer Sa | Procede de preparation de genomes d'adenovirus recombinants |
JP3770333B2 (ja) | 1995-03-15 | 2006-04-26 | 大日本住友製薬株式会社 | 組換えdnaウイルスおよびその製造方法 |
US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
US6019978A (en) | 1995-06-05 | 2000-02-01 | The Wistar Institute Of Anatomy And Biology | Replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
US5704910A (en) * | 1995-06-05 | 1998-01-06 | Nephros Therapeutics, Inc. | Implantable device and use therefor |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
CA2177085C (en) | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Adenovirus e1-complementing cell lines |
WO1998013499A2 (en) | 1996-09-25 | 1998-04-02 | Novartis Ag | Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors |
US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
US5998598A (en) | 1997-03-10 | 1999-12-07 | The United States Of America, As Represented By The Department Of Health And Human Services | Immunoadhesins and methods of production and use thereof |
US5981275A (en) | 1997-04-14 | 1999-11-09 | Genzyme Corporation | Transgene expression system for increased persistence |
US5849561A (en) | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
EP1027069B1 (en) * | 1997-10-29 | 2006-07-26 | Genzyme Corporation | Gene therapy for gaucher disease |
US5922576A (en) | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
US6492343B1 (en) * | 1998-04-15 | 2002-12-10 | University Of Saskatchewan | Porcine adenovirus type 3 genome |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
EP1108049A2 (en) * | 1998-08-28 | 2001-06-20 | Duke University | Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences |
US6326958B1 (en) * | 1999-05-14 | 2001-12-04 | Zight Corporation | Power partitioned miniature display system |
-
1999
- 1999-08-27 EP EP99943952A patent/EP1108049A2/en not_active Withdrawn
- 1999-08-27 CA CA002340276A patent/CA2340276A1/en not_active Abandoned
- 1999-08-27 CN CN99812228A patent/CN1342206A/zh active Pending
- 1999-08-27 JP JP2000567725A patent/JP2002528056A/ja active Pending
- 1999-08-27 IL IL14140399A patent/IL141403A0/xx unknown
- 1999-08-27 AU AU56942/99A patent/AU764686B2/en not_active Ceased
- 1999-08-27 WO PCT/US1999/019540 patent/WO2000012740A2/en not_active Application Discontinuation
- 1999-08-27 US US09/384,749 patent/US6328958B1/en not_active Expired - Lifetime
-
2001
- 2001-10-05 US US09/972,794 patent/US6797265B2/en not_active Expired - Lifetime
-
2003
- 2003-11-25 AU AU2003262493A patent/AU2003262493A1/en not_active Abandoned
-
2004
- 2004-09-07 US US10/935,576 patent/US7666405B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6328958B1 (en) | 2001-12-11 |
JP2002528056A (ja) | 2002-09-03 |
US6797265B2 (en) | 2004-09-28 |
US7666405B2 (en) | 2010-02-23 |
US20030165462A1 (en) | 2003-09-04 |
AU2003262493A1 (en) | 2004-01-08 |
CN1342206A (zh) | 2002-03-27 |
CA2340276A1 (en) | 2000-03-09 |
AU5694299A (en) | 2000-03-21 |
WO2000012740A2 (en) | 2000-03-09 |
EP1108049A2 (en) | 2001-06-20 |
WO2000012740A3 (en) | 2000-11-23 |
AU764686B2 (en) | 2003-08-28 |
US20050019929A1 (en) | 2005-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL141403A0 (en) | Deleted adenoviruses and methods of making and administering the same | |
IL120124A0 (en) | Heteroaryl-oxazolidinones their preparation and use | |
ZA982478B (en) | Compounds their use and preparation | |
GB9813271D0 (en) | Composition and use | |
AU8967998A (en) | Antibiotic-ligand conjugates and methods of use thereof | |
GB9806666D0 (en) | Antigen preparation and use | |
AU7401598A (en) | Epoxide-amine dendrimers and the preparation and use thereof | |
HUP0000963A3 (en) | The use of levobupivacaine in paediatric surgery | |
GB2367103B (en) | Connector and method of use of the connector | |
GB9811168D0 (en) | Direct hair-colouring compositions and the use thereof | |
IL141426A0 (en) | Compositions and methods for the treatment of tumor | |
IL143212A0 (en) | Compositions and methods for the treatment of tumor | |
GB9823245D0 (en) | Pectins and the preparation thereof | |
EP1139981A4 (en) | COMPOSITIONS AND RELATED METHODS OF USE | |
PL348871A1 (en) | Organophosphorous compounds and the use thereof | |
AU2529799A (en) | Benzofuran-4-carboxamides and their therapeutic use | |
HUP0104723A3 (en) | New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use | |
GB9606579D0 (en) | Pharmaceutical composition and methods for the manufacture thereof | |
AU3964499A (en) | Agouti-related protein analogs and methods of use | |
PL328334A1 (en) | Preparation and application thereof | |
AU4629399A (en) | Substituted piperazones and their therapeutic uses | |
EP1112250A4 (en) | THERAPEUTIC COMPOUNDS AND RELATED METHODS | |
ZA9711669B (en) | Cyanophosphorus compounds and their preparation | |
GB9617346D0 (en) | Therapeutic methods and compositions for use therein | |
EP1150967A4 (en) | THERAPEUTICALLY APPLICABLE CONNECTIONS AND METHODS |